Core Viewpoint - Viemed Healthcare is upgraded to a 'Buy' rating following a strong Q2 earnings report and positive technical indicators, despite previous concerns about growth and market trends [2][3]. Technical Analysis - A bullish crossover of the MACD indicator suggests a potential upward trend for Viemed's stock, indicating favorable conditions for price appreciation [3]. - The stock has recently broken above a bearish trend line, and while it faces resistance at the 200-day moving average of approximately $7.78, there is optimism for overcoming this barrier [6]. - Strong buying volume has been observed despite a 27% decline from March highs of approximately $10, indicating potential for a price rebound [6][7]. Encouraging Q2 Trends - Viemed reported record revenue of $55 million in Q2, reflecting a 27% rolling quarter growth and an increase in active ventilator patients by 4.4% [8]. - The restructuring of the sales team has led to improved performance and increased reach to patients, suggesting a scalable growth model for the company's ventilator business [9]. - The introduction of GLP1 drugs has not negatively impacted Viemed's sleep business; instead, it has heightened awareness and sustained growth in CPAP and sleep product lines [10]. Strategic Opportunities - The recall of Philips' ventilators presents a unique opportunity for Viemed to upgrade its fleet through a buy-back agreement, allowing for the replacement of older units without negatively impacting cash flows [11]. - The company is leveraging volume purchase discounts to enhance its inventory while reducing servicing costs associated with older machines [11]. Valuation Perspective - Viemed's trailing GAAP multiple of nearly 32 may seem high, but its sales and book multiples are significantly below 5-year averages, indicating attractive valuation for potential earnings growth [12]. - The company's trailing price-to-sales ratio is 1.37, which is 45.9% lower than its 5-year average, and the price-to-book ratio is 2.38, 40.3% below its historical average [12]. Conclusion - Continued investments in technology, particularly the Engage platform, alongside positive technical indicators and growing patient counts, suggest a favorable outlook for Viemed's share price in the near term [13].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Title of each class Trading Symbol(s) Name of exchange on which registered Common Shares, no par value VMD The Nasdaq Stock Market LLC ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number: ...

Core Insights - Viemed Healthcare, Inc. reported record net revenues of $55.0 million for the quarter ended June 30, 2024, marking a 27% increase compared to the same quarter in 2023 [2] - The company achieved a net income of $1.5 million and an adjusted EBITDA of $12.8 million, reflecting a 31% increase year-over-year [3] - Viemed's ventilator patient count reached a record high of 10,905, representing a 4.4% sequential increase from the previous quarter [4] Financial Performance - Net revenues for Q2 2024 were $55.0 million, up from $43.3 million in Q2 2023, indicating a growth of $11.7 million [2] - Adjusted EBITDA for Q2 2024 was $12.8 million, compared to $9.8 million in Q2 2023, showing a significant increase [3][19] - The company reported a net income of $1.5 million for Q2 2024, compared to $2.3 million in Q2 2023 [3][19] Operational Highlights - The number of ventilator patients increased to 10,905 as of June 30, 2024, up from 10,450 at the end of Q1 2024 [4][19] - The company maintains a cash balance of $8.8 million and total working capital of $13.5 million as of June 30, 2024 [4] - Viemed expects to generate net revenues of approximately $56.5 million to $57.7 million in Q3 2024 [5] Management Commentary - CEO Casey Hoyt emphasized the organic growth of complex respiratory services, highlighting the substantial demand and Viemed's commitment to addressing the needs of an underserved market [6]

LAFAYETTE, La., July 24, 2024 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it will host its Quarterly Conference Call on Thursday, August 8, 2024 at 11:00 a.m. ET. Financial professionals are invited to call in to register in advance to ask questions. To pre-register as a qualified caller, please e-mail investorinfo@viemed.com by 12:00 p.m. ET Wednesday, ...

Interested parties may participate in the call by dialing: Financial professionals are invited to call in to register in advance to ask questions. To pre-register as a qualified caller, please e-mail investorinfo@viemed.com by 12:00 p.m. ET Wednesday, August 7, 2024. Following the live call, a replay will be available in the Investor Relations section of the Company's website, www.viemed.com. ABOUT VIEMED HEALTHCARE, INC. Viemed is a provider of in-home medical equipment and post-acute respiratory healthcar ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number: 001-38973 Viemed Healthcare, Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada N/A (State or other ...

VIEMED HEALTHCARE ANNOUNCES FIRST QUARTER 2024 FINANCIAL RESULTS Lafayette, Louisiana (May 6, 2024) Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it has reported its financial results for the three months ended March 31, 2024. Operational highlights (all dollar amounts are USD): For further information, please contact: "I am tremendously enthusiastic about the Company's perf ...

Viemed Healthcare, Inc. (NASDAQ:VMD) Q4 2023 Earnings Conference Call March 7, 2024 11:00 AM ET Company Participants Todd Zehnder - COO Casey Hoyt - CEO Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Doug Cooper - Beacon Securities Eric Coldwell - Baird Operator Greetings, and welcome to the Viemed Fourth Quarter 2023 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Todd Zehnder, Chief Operating O ...

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C.7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐ | UNITED | STATES | | --- | --- | | SECURITIES | AND EXCHANGE COMMISSION | | Washington, D.C. 20549 | | | Form | 10-K | | ☒ | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF T ...

[VIEMED HEALTHCARE ANNOUNCES RECORD 2023 FINANCIAL RESULTS](index=1&type=section&id=VIEMED%20HEALTHCARE%20ANNOUNCES%20RECORD%202023%20FINANCIAL%20RESULTS) [Financial and Operational Highlights](index=1&type=section&id=Financial%20and%20Operational%20Highlights) Viemed Healthcare achieved record 2023 financial results, marked by significant revenue and net income growth, alongside robust cash flow generation Q4 and Full Year 2023 vs 2022 Performance | Metric | Q4 2023 | Q4 2022 | % Change | Full Year 2023 | Full Year 2022 | % Change | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Net Revenues | $50.7M | $37.5M | +35% | $183.0M | $138.8M | +32% | | Net Income | $3.5M | $2.4M | +43% | $10.2M | $6.2M | +65% | Adjusted EBITDA Performance | Period | Adjusted EBITDA | | :--- | :--- | | Q4 2023 | $12.8M | | Full Year 2023 | $43.1M | Full Year 2023 vs 2022 Cash Flow | Metric | Full Year 2023 | Full Year 2022 | % Change | | :--- | :--- | :--- | :--- | | Net Cash from Operating Activities | $45.2M | $27.7M | +62.9% | | Free Cash Flow | $19.1M | $4.8M | +294% | - As of December 31, 2023, the company maintained a cash balance of **$12.8 million** and had long-term debt of **$6.0 million**[5](index=5&type=chunk) - After a **~$30 million acquisition** in 2023, Viemed ended the year with no net debt and has approximately **$53 million** available under its credit facilities[5](index=5&type=chunk) [Financial Outlook](index=1&type=section&id=Financial%20Outlook) The company projects Q1 2024 net revenues between $49.7 million and $51.0 million, assuming no extension of specific Medicare reimbursement rate adjustments Q1 2024 Net Revenue Guidance | Metric | Guidance Range | | :--- | :--- | | Net Revenues | $49.7M - $51.0M | - The guidance assumes that the 75/25 blended Medicare reimbursement rate adjustment in non-rural, non-competitive bid areas will not be extended[5](index=5&type=chunk) [Consolidated Financial Statements](index=4&type=section&id=Consolidated%20Financial%20Statements) Consolidated financial statements for 2023 show significant growth in total assets and shareholders' equity, driven by an acquisition and increased liabilities [Consolidated Balance Sheets](index=4&type=section&id=Consolidated%20Balance%20Sheets) As of December 31, 2023, total assets increased to $154.9 million, driven by an acquisition, while liabilities and shareholders' equity also grew Key Balance Sheet Items (in thousands) | Account | Dec 31, 2023 | Dec 31, 2022 | | :--- | :--- | :--- | | Cash and cash equivalents | $12,839 | $16,914 | | Goodwill | $29,765 | $0 | | Total Assets | $154,895 | $117,043 | | Long-term debt | $6,002 | $0 | | Total Liabilities | $41,000 | $19,949 | | Total Shareholders' Equity | $113,895 | $97,094 | [Consolidated Statements of Income and Comprehensive Income](index=5&type=section&id=Consolidated%20Statements%20of%20Income%20and%20Comprehensive%20Income) Full year 2023 saw a 32% revenue increase to $183.0 million and a 65% net income growth to $10.2 million, with diluted EPS rising to $0.25 Full Year Income Statement Highlights (in thousands, except per share data) | Metric | Year Ended Dec 31, 2023 | Year Ended Dec 31, 2022 | | :--- | :--- | :--- | | Revenue | $183,008 | $138,832 | | Gross Profit | $112,783 | $84,680 | | Income from Operations | $14,330 | $8,252 | | Net Income | $10,243 | $6,222 | | Diluted EPS | $0.25 | $0.16 | [Consolidated Statements of Cash Flows](index=6&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) Net cash from operating activities increased by 63% to $45.2 million in 2023, while significant investing activities led to a net decrease in cash Cash Flow Summary (in thousands) | Activity | Year Ended Dec 31, 2023 | Year Ended Dec 31, 2022 | | :--- | :--- | :--- | | Net cash provided by operating activities | $45,212 | $27,748 | | Net cash used in investing activities | ($52,113) | ($23,976) | | Net cash provided by (used in) financing activities | $2,826 | ($15,266) | | Net decrease in cash and cash equivalents | ($4,075) | ($11,494) | [Non-GAAP Financial Measures](index=7&type=section&id=Non-GAAP%20Financial%20Measures) The company uses non-GAAP measures like Adjusted EBITDA ($43.1 million) and Free Cash Flow ($19.1 million) to provide additional insight into financial performance - Adjusted EBITDA is defined as net income before interest, taxes, depreciation & amortization, stock-based compensation, and acquisition-related transaction costs[16](index=16&type=chunk) - Free Cash Flow is defined as net cash provided by operating activities less cash paid for purchases of property and equipment[20](index=20&type=chunk) Reconciliation to Non-GAAP Measures for Full Year 2023 (in thousands) | Measure | Calculation | Amount | | :--- | :--- | :--- | | **Adjusted EBITDA** | | | | Net Income | | $10,243 | | Add: D&A, Interest, Taxes, etc. | | $32,821 | | **Adjusted EBITDA** | | **$43,064** | | **Free Cash Flow** | | | | Net cash from operating activities | | $45,212 | | Less: Purchase of property & equipment | | ($26,093) | | **Free Cash Flow** | | **$19,119** | [Key Financial and Operational Information](index=9&type=section&id=Key%20Financial%20and%20Operational%20Information) Viemed demonstrated consistent quarterly growth in revenue and active ventilator patients throughout 2022 and 2023 Quarterly Revenue and Vent Patient Growth (2022-2023) | Quarter Ended | Revenue (in thousands) | Vent Patients (End of Period) | | :--- | :--- | :--- | | Mar 31, 2022 | $32,255 | 8,434 | | Jun 30, 2022 | $33,310 | 8,837 | | Sep 30, 2022 | $35,759 | 9,127 | | Dec 31, 2022 | $37,508 | 9,306 | | Mar 31, 2023 | $39,556 | 9,337 | | Jun 30, 2023 | $43,311 | 10,005 | | Sep 30, 2023 | $49,402 | 10,244 | | Dec 31, 2023 | $50,739 | 10,327 |